Re:Cognition Health
Brain and Mind Experts

Specialised Care for Alzheimer's Patients

At Re:Cognition Health's Brain and Mind Clinics

Information for referring clinicians.

“Our mission is to deliver advanced Alzheimer’s treatments to your patients with clinical experience and expertise.”

Welcome to Re:Cognition Health

At Re:Cognition Health we provide accurate, holistic, and tailored care to your patients. In order to better assist you with the process and your visit in our clinic, we have developed this leaflet in the hope of providing more information and guidance.

Our international team of Brain and Mind Experts have undertaken over 150 international clinical trials for new generation disease-modifying treatments for Alzheimer's Disease.

We have administered over 9,000 intravenous treatments for the new amyloid monoclonal antibody treatments for early Alzheimer's disease within clinical trials.

Re:Cognition Health Experienced Experts in the USA & UK are now accepting referrals for MHRA-approved Alzheimer's therapies, Lecanemab and Donanemab.

Please get in touch to see how we can help your patients.

Dr Emer MacSweeney, Consultant Neuroradiologist and CEO

How we can help you

Eligibility Verification: Assistance with patient screening and insurance pre-authorisation.

Expert Infusion Services: Skilled administration by experienced staff in a comfortable setting.

Ongoing Communication: Our experts wish to collaborate with patient's referring doctors to provide safe and experienced management of the treatment program.

Convenient Locations: Central London and Bristol.

Overview of treatments

Lecanemab or Donanemab reduce elevated levels of toxic brain amyloid protein which correlated with slowing of cognitive decline in Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD) dementia.

The following are required to meet the eligibility criteria for treatment:

- Elevated brain amyloid protein (the hallmark for AD) via PET amyloid scan or CSF analysis
- Mild cognitive impairment (MCI) or mild AD dementia.
- ApoE gene testing (APOE 4/4 is exclusionary)
- Brain MRI prior to initiation of treatment.

Unparalleled expertise

Re:Cognition Health: Expertise in Managing ARIA
At Re:Cognition Health, the management of ARIA is a key focus. Our teams have given over 9000 doses of this type of medication for Alzheimer's disease and have vast expertise in utilising advanced imaging technologies and interpreting MRI results, to ensure safe management of our patients.

Dr Emer MacSweeney, the CEO, Medical Director at ReCognition Health, is also a Consultant Neuroradiologist and alongside her team of cognitive specialists is adept at identifying ARIA early and tailoring treatment strategies to each patient's unique needs.

The clinic's approach includes not only routine MRI monitoring but also a personalised management plan that considers the patient's overall health, risk factors and response to treatment. By staying ahead of potential complications and addressing them promptly, Re:Cognition Health's experts are dedicated to maximising the benefits of new Alzheimer's therapies while minimising risks.

Click to listen to Dr MacSweeney speak about ARIA

Our simple referral process

To refer a patient to us, simply email referrals@re-cognitionhealth.com and our team will handle eligibility verification and scheduling.

Contact us

UK Private Practice is available Nationwide via “virtual consultation” and “face to face” at Re:Cognition Health Clinics in:

London
72-64 New Cavendish St.
London, W1G 8TA
0203 808 5439

Bristol
Unit 240, Phase 200, Aztec West,
Bristol, BS32 4SY
0117 205 0377

www.recognitionhealth.com
referrals@re-cognitionhealth.com

Re:Cognition Health
Brain and Mind Experts